Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children
2 other identifiers
observational
667
1 country
4
Brief Summary
This is a descriptive prospective community-based seroprevalence study. Primary objective:
- To determine the prevalence of specific antibodies (immunoglobulin G \[IgG\]) against dengue in healthy 5 to 10 year-old children in India. Secondary objectives:
- To determine the dengue virus serotype (DeNV-1,2,3 and /or 4) specific to the antibodies in positive (IgG) samples
- To estimate the prevalence of specific antibodies (IgG) against Japanese encephalitis in healthy 5 to 10 year-old children in India.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2011
Typical duration for all trials
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2011
CompletedFirst Submitted
Initial submission to the registry
November 18, 2011
CompletedFirst Posted
Study publicly available on registry
November 22, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2013
CompletedJanuary 11, 2018
January 1, 2018
1 year
November 18, 2011
January 9, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Prevalence of positive samples with dengue specific serotype DENV 1, 2,3 and/or 4
Baseline
Secondary Outcomes (1)
Prevalence of positive serum samples with JEV specific IgG antibodies
Baseline
Study Arms (1)
Study Group
Participants aged between 5 and 10 year-old on day of inclusion.
Eligibility Criteria
Participants aged between 5 and 10 year-old that are registered in health centers in India.
You may qualify if:
- Healthy child as reported by the parent or legally qualified guardian
- Being registered in selected study site
- Provision of the informed consent form signed by at least one parent or legally qualified guardian
- For children between 8 and 10 years old, provision of the assent form signed.
You may not qualify if:
- N/A
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
Unknown Facility
Kalyani, West Bengali, 741235, India
Unknown Facility
Bangalore, 560070, India
Unknown Facility
Hyderabad, 500063, India
Unknown Facility
New Delhi, 110002, India
Related Publications (2)
Garg S, Chakravarti A, Singh R, Masthi NR, Goyal RC, Jammy GR, Ganguly E, Sharma N, Singh MM, Ferreira G, Moureau A, Ojha S, Nealon J; DNG10 study group. Dengue serotype-specific seroprevalence among 5- to 10-year-old children in India: a community-based cross-sectional study. Int J Infect Dis. 2017 Jan;54:25-30. doi: 10.1016/j.ijid.2016.10.030. Epub 2016 Nov 4.
PMID: 27825949RESULTBhavsar A, Tam CC, Garg S, Jammy GR, Taurel AF, Chong SN, Nealon J. Estimated dengue force of infection and burden of primary infections among Indian children. BMC Public Health. 2019 Aug 14;19(1):1116. doi: 10.1186/s12889-019-7432-7.
PMID: 31412836DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Medical Director
Sanofi Pasteur SA
Study Design
- Study Type
- observational
- Observational Model
- ECOLOGIC OR COMMUNITY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 18, 2011
First Posted
November 22, 2011
Study Start
September 1, 2011
Primary Completion
September 1, 2012
Study Completion
December 1, 2013
Last Updated
January 11, 2018
Record last verified: 2018-01